FDA WARNING_LETTER - Camelot E-Liquid - April 02, 2019

On March 6, 2019, the FDA issued a Warning Letter to Camelot E-Liquid, specifically to James Shearon, following a review of their website, http://cameloteliquid.com. The FDA determined that Camelot King Arthur e-liquid, manufactured and sold by Camelot E-Liquid, is a tobacco product under section 201(rr) of the FD&C Act.

The primary violation identified was the sale of Camelot King Arthur e-liquid to a person younger than 18 years of age, which constitutes misbranding under section 903(a)(7)(B) of the FD&C Act (21 U.S.C. § 387c(a)(7)(B)). This violates 21 C.F.R. § 1140.14(b), which prohibits retailers from selling covered tobacco products, including e-liquids, to minors.

Camelot E-Liquid is required to immediately correct this violation and any similar issues, ensuring all tobacco products and related advertising comply with the FD&C Act and FDA regulations. Failure to comply may result in further FDA actions, including civil money penalties, no-tobacco-sale orders, criminal prosecution, seizure, and/or injunction. A written response detailing corrective actions, including dates of discontinuation of violative sales and a plan for maintaining compliance, must be submitted within 15